Bladder Cancer Real-World Immunotherapy Dataset for AI LLM

Patients with advanced bladder cancer treated with Atezolizumab have shown significantly better response rates and survival than historical controls receiving second-line chemotherapy. The toxicity profile is also favorable—making it one of the most impactful developments in uro-oncology in the past decade.

But the opportunity doesn’t stop there.

Today, we’re excited to introduce a structured, AI-ready dataset covering the complete trial and pharmacologic journey of Atezolizumab in bladder cancer—from Phase I safety and biomarker profiles to Phase II/III survival outcomes and emerging front-line use cases.

Why This Dataset Matters

Comprehensive Clinical Coverage Covers PCD4989G, IMvigor210, IMvigor211, IMvigor010, IMvigor130, GU123, and more. Includes dosing, efficacy, safety, irAEs, biomarkers, endpoints, and survival outcomes.

Built for AI & LLM Training The dataset is formatted in prompt-completion JSON, ideal for:

• Fine-tuning medical LLMs

• Building oncology-specific Q&A agents

• Training CDSS (Clinical Decision Support Systems)

• Powering patient engagement and decision explainers

Bridges Clinical and Translational Research Includes data on:

• PD-L1 IHC scoring (SP142)

• Tumor-infiltrating immune cell correlations

• Tumor mutation burden (TMB) and IFNγ signature data

• Biomarker-survival response dynamics across stages

Use Cases for Buyers & Collaborators

AI & HealthTech Startups: Accelerate your model development with clean, annotated, oncology-rich data. 🏥 Hospitals & CROs: Use this for protocol design, digital twins, or patient eligibility modeling. 🔬 Pharma & Biotech: Inform trial strategies, benchmark immunotherapy, and design next-gen companion diagnostics. 📚 Academic Researchers: Integrate structured datasets into bioinformatics pipelines or survival prediction models.

The Road Ahead

Atezolizumab is currently being studied in earlier-stage disease settings, including adjuvant trials (IMvigor010) and non-muscle–invasive cases (GU123). Our dataset evolves as the evidence base grows—positioning your AI solutions or research to stay current and clinically grounded.

Sample Dataset for AI LLM Training in JSON

[
  {  "prompt": "How is PD-L1 expression linked to outcomes in bladder cancer?",
    "completion": "In bladder cancer, PD-L1 expression is associated with higher tumor grade, advanced stage, poor response to BCG immunotherapy, and worse survival outcomes."
  },
  {
    "prompt": "What is atezolizumab and how does it act on the PD-L1 pathway?",
    "completion": "Atezolizumab is a fully humanized IgG1 monoclonal antibody that selectively blocks PD-L1 from binding to PD-1 and B7.1, enhancing T-cell-mediated antitumor immunity."
  },
  {
    "prompt": "Does atezolizumab block PD-L2 interactions with PD-1?",
    "completion": "No, atezolizumab does not block the interaction between PD-L2 and PD-1."
  },
  {
    "prompt": "What is the pharmacokinetic profile of atezolizumab in preclinical models?",
    "completion": "In preclinical models, atezolizumab shows limited volume of distribution consistent with plasma volume and accumulates in organs like spleen, lungs, and tumor tissue."
  },
  {
    "prompt": "How does atezolizumab distribute in tumor-bearing animals?",
    "completion": "Atezolizumab accumulates initially at the tumor periphery and later penetrates the tumor core, particularly in necrotic areas."
  },
  {
    "prompt": "Why is the pharmacokinetics of atezolizumab nonlinear?",
    "completion": "Atezolizumab exhibits nonlinear pharmacokinetics due to target-mediated drug disposition involving binding to PD-L1 receptors."
  },
  {
    "prompt": "At what serum concentration does PD-L1 receptor saturation occur with atezolizumab?",
    "completion": "Saturation of PD-L1 on CD4 and CD8 T cells occurs at serum concentrations above 0.5 μg/mL, typically between 24–48 hours after dosing."
  },


  {
    "prompt": "What was the dosing range of atezolizumab in the PCD4989G trial?",
    "completion": "Atezolizumab was administered at doses ranging from 0.03 to 20 mg/kg every 3 weeks."
  },
  {
    "prompt": "What trough level is required for 95% saturation of intratumoral PD-L1 receptors in murine models?",
    "completion": "A trough level greater than 6 μg/mL results in over 95% saturation of PD-L1 receptors in murine models."
  },
  {
    "prompt": "What is the proposed optimal dose of atezolizumab for future studies?",
    "completion": "The proposed optimal dose is 1,200 mg, assuming an 80 kg person."
  },
  {
    "prompt": "How long is the infusion time for atezolizumab in initial and subsequent cycles?",
    "completion": "Atezolizumab is infused over 60 minutes for the first cycle and 30 minutes in subsequent cycles if well tolerated."
}
]

📩 Interested in collaborating or licensing the dataset? Let’s connect to explore pilot access, integration support, or co-development opportunities.

🔗 www.ieearc.com 📬 Or DM me directly here on LinkedIn.

Let’s shape the future of cancer care—one data-driven breakthrough at a time.

#Atezolizumab #BladderCancer #Immunotherapy #ClinicalTrials #LLM #AIinHealthcare #PrecisionOncology #MedicalData #DrugDevelopment #PDL1 #CancerResearch #LLMTraining